Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Total Current Liabilities (2016 - 2025)

Catalyst Pharmaceuticals' Total Current Liabilities history spans 16 years, with the latest figure at $147.2 million for Q4 2025.

  • For Q4 2025, Total Current Liabilities rose 21.94% year-over-year to $147.2 million; the TTM value through Dec 2025 reached $147.2 million, up 21.94%, while the annual FY2025 figure was $147.2 million, 21.94% up from the prior year.
  • Total Current Liabilities reached $147.2 million in Q4 2025 per CPRX's latest filing, up from $128.7 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $147.2 million in Q4 2025 to a low of $14.4 million in Q1 2021.
  • Average Total Current Liabilities over 5 years is $68.4 million, with a median of $57.7 million recorded in 2022.
  • Peak YoY movement for Total Current Liabilities: decreased 20.16% in 2021, then surged 147.23% in 2023.
  • A 5-year view of Total Current Liabilities shows it stood at $27.1 million in 2021, then surged by 112.79% to $57.6 million in 2022, then surged by 32.08% to $76.1 million in 2023, then soared by 58.66% to $120.7 million in 2024, then rose by 21.94% to $147.2 million in 2025.
  • Per Business Quant, the three most recent readings for CPRX's Total Current Liabilities are $147.2 million (Q4 2025), $128.7 million (Q3 2025), and $113.0 million (Q2 2025).